Dr. Wierda Discusses Sequencing New Agents in CLL

William G. Wierda, MD, PhD
Published: Tuesday, Oct 17, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia (CLL).

With a plethora of novel agents approved in CLL, sequencing has become a central topic of discussion.

Some updates include the approval of venetoclax (Venclexta), which Wierda says is being considered for combination with existing agents or possibly a CD20-targeted monoclonal antibody to get better remissions.
 


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia (CLL).

With a plethora of novel agents approved in CLL, sequencing has become a central topic of discussion.

Some updates include the approval of venetoclax (Venclexta), which Wierda says is being considered for combination with existing agents or possibly a CD20-targeted monoclonal antibody to get better remissions.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x